How ESE is Funded

The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2020 financial year.

ESE is funded through a number of industry and non-industry sources;

  • Membership – individual
  • Membership – Corporate – See all our Corporate members
  • Revenue generated by ESE owned journal ‘European Journal of Endocrinology
  • Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education 
  • The list of all industry and non-industry revenue sources in 2020 are listed below: 
  1. Advanced Accelerator Applications
  2. Akcea Theraputics
  3. Alexion
  4. Amryt Pharmaceuticals DAC
  5. Ascendis Pharma
  6. Brahms GMBH
  7. Chiasma
  8. Clinical Endocrinology Trust
  9. Crinetics Pharmaceuticals
  10. Diurnal
  11. Gilead Sciences Europe
  12. Health Unlimited
  13. HRA Pharma
  14. International Medical Press
  15. Ipsen
  16. ITM Isotopen Technologien Munchen AG
  17. Kyowa Kirin International Plc
  18. Liberum
  19. Novo Nordisk
  20. Pfizer
  21. Recordati
  22. Sandoz
  23. Siemens
  24. Strongbridge
  25. Takeda/Shire
  26. Thyroid Federation
  27. Unipharma
  • Of the revenue into ESE in the 2020 accounts 62.3% was provided by industry.
  • The highest contribution from a single company represented 15.9% of the industry revenue and 9.9% of ESE revenue overall.